Skip to main content

Table 1 Reductions in mean sitting DBP (msDBP) and mean sitting DBP (msSBP)

From: Clinical efficacy, safety and tolerability of Aliskiren Monotherapy (AM): an umbrella review of systematic reviews

OutcomeNo. of SRsNo. of original studiesNo. of cases/ controlsFollow-up range (weeks)Estimate (95%CI)P- value95%PII2(P*)Egger’s P value
msDBP
 aliskiren75mg vs placebo15821/2798–13− 2.05 [− 3.13,-0.96]< 0.001[− 3.81,-0.28]0%(0.73)0.043
 aliskiren150mg vs placebo1122665/11188–26−3.19 [−4.02, -2.37]< 0.001[−5.57,-0.82]47%(0.04)0.798
 aliskiren300mg vs placebo1102193/8088–26−4.51 [−5.27, −3.76]< 0.001[− 5.97, − 3.06]17%(0.29)0.359
 aliskiren600mg vs placebo12296/978−5.86 [−7.73, -3.99]< 0.0001NA0%(0.57)NA
 aliskiren vs ARBs (low dose)24648/5324–80.07 [−0.94,1.09]0.89[−2.15,2.30]0%(0.48)0.12
 aliskiren vs ARBs (low to high dose)25923/9448–12−0.25 [−2.32,1.82]0.81[−7.82,7.31]82% (0.0002)0.272
 aliskiren vs ARBs (high dose)23241/1228−0.65 [−2.52, 1.23]0.5[−12.79,11.49]0%(0.89)0.293
 aliskiren vs ACEIs23796/786≥8−1.19[− 1.99, −0.38]0.004[−6.42,4.05]0%(0.53)0.687
 aliskiren vs amlodipine11203/18183.63 [1.85,5.41]< 0.0001NANANA
 aliskiren vs HCTZ11183/1768−0.9 [−2.56,0.76]0.29NANANA
 aliskiren vs atenolol11231/231122.4 [0.74,4.06]0.004NANANA
 Aliskiren150mg vs 75 mg15830/8248–13−0.8 [−1.58,-0.03]0.04[−2.06,0.04]0%(0.45)0.944
 aliskiren300mg vs 150 mg1102193/21958–26−1.75 [−2.31, − 1.20]< 0.001[− 2.88,-0.63]20%(0.26)0.584
 aliskiren600mg vs 300 mg12296/2968−0.68[−2.03,0.67]0.449NA33%(0.22)NA
msSBP
 aliskiren75mg vs placebo15821/2798–13−2.97[−4.76, -1.18]0.001[−5.88,-0.66]0%(0.57)0.253
 aliskiren150mg vs placebo1122665/11218–26−5.93[−6.94, -4.91]< 0.001[−7.93,-3.92]17%(0.28)0.674
 aliskiren300mg vs placebo1102199/8108–26−7.91 [−9.15, −6.67]< 0.001[−10.48,-5.33]22%(0.24)0.693
 aliskiren600mg vs placebo12296/978−11.35[− 14.43,-8.27]< 0.00001NA0%(0.62)NA
 aliskiren vs ARBs (low dose)24648/5324–81.25 [−0.29,2.78]0.111[−2.57,5.06]6%(0.36)0.661
 aliskiren vs ARBs (low to high dose)25923/9448–12−1.19[−4.09, 1.70]0.42[−11.46,9.08]77% (0.002)0.242
 aliskiren vs ARBs (high dose)23241/12280.24 [−2.29, 2.76]0.85[−16.10,16.57]0%(0.65)0.841
 aliskiren vs ACEIs241253/1230≥8−2.37[−3.48, −1.26]< 0.0001[−4.83,0.04]0%(0.59)0.123
 aliskiren vs amlodipine11203/18185.67 [2.86,8.48]< 0.0001NANANA
 aliskiren vs HCTZ11183/1768−1.4 [−4.04,1.24]0.3NANANA
 aliskiren vs atenolol11231/23112−0.08 [−3.02,2.86]0.96NANANA
 aliskiren150mg vs 75 mg15830/8218–13−1.89 [−3.34, −0.43]0.011[−5.37,1.59]23%(0.27)0.872
 aliskiren300mg vs 150 mg1102199/21958–26−2.57 [−3.72, −1.42]< 0.0001[− 5.87,0.73]52%(0.03)0.921
 aliskiren600mg vs 300 mg12296/2968−0.61 [−2.78, 1.56]0.581NA0%(0.60)NA
  1. Notes: Type of metric: WMD (Weighted mean difference)
  2. Abbreviations: NA Not Accessible, SR Systematic review